Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

CFRX | ContraFect Corp

Index- P/E- EPS (ttm)-53.49 Insider Own0.10% Shs Outstand10.70M Perf Week-6.19%
Market Cap5.67M Forward P/E- EPS next Y-1.95 Insider Trans0.00% Shs Float10.69M Perf Month-26.19%
Income-35.84M PEG- EPS next Q-0.72 Inst Own1.14% Short Float / Ratio0.13% / 0.24 Perf Quarter-64.31%
Sales0.00M P/S- EPS this Y96.93% Inst Trans-85.35% Short Interest0.01M Perf Half Y-77.25%
Book/sh-0.10 P/B- EPS next Y48.68% ROA-119.38% Target Price5.00 Perf Year-96.26%
Cash/sh1.35 P/C0.39 EPS next 5Y12.70% ROE-608.73% 52W Range0.51 - 15.76 Perf YTD-93.10%
Dividend- P/FCF- EPS past 5Y11.02% ROI-4073.30% 52W High-96.64% Beta0.52
Dividend %- Quick Ratio1.00 Sales past 5Y0.00% Gross Margin- 52W Low3.92% ATR0.09
Employees23 Current Ratio1.00 Sales Q/Q- Oper. Margin0.00% RSI (14)26.02 Volatility11.91% 14.32%
OptionableNo Debt/Eq- EPS Q/Q94.73% Profit Margin- Rel Volume0.72 Prev Close0.58
ShortableYes LT Debt/Eq- EarningsAug 14 BMO Payout- Avg Volume59.69K Price0.53
Recom1.00 SMA20-19.79% SMA50-39.86% SMA200-81.79% Volume43,126 Change-8.62%
Date Action Analyst Rating Change Price Target Change
Jul-14-22Downgrade SVB Leerink Outperform → Mkt Perform $1
Jul-14-22Downgrade Cantor Fitzgerald Overweight → Neutral $15 → $1
Feb-02-22Upgrade WBB Securities Speculative Buy → Buy $6.50
Sep-09-21Initiated SVB Leerink Outperform $14
Jun-09-20Initiated Mizuho Buy $12
Jun-09-20Initiated Cantor Fitzgerald Overweight $15
Jul-28-16Initiated Piper Jaffray Overweight
Jul-22-16Downgrade Maxim Group Buy → Hold
Mar-15-16Reiterated Maxim Group Buy $8 → $7
Dec-31-15Reiterated Maxim Group Buy $16 → $9
Sep-21-23 09:40AM
Sep-19-23 08:30AM
Sep-18-23 07:30AM
Aug-28-23 08:00AM
Aug-17-23 09:41AM
08:38AM Loading…
Aug-14-23 08:38AM
Jun-27-23 08:30AM
Jun-22-23 07:06AM
Jun-20-23 08:59AM
Jun-08-23 04:01PM
May-23-23 06:31AM
May-15-23 08:16AM
Apr-27-23 04:24PM
09:00AM Loading…
Apr-26-23 09:00AM
Apr-20-23 08:30AM
Apr-13-23 06:26AM
Apr-06-23 08:30AM
Apr-03-23 08:30AM
Mar-31-23 08:30AM
Feb-28-23 08:30AM
Dec-20-22 09:35AM
Dec-19-22 04:30PM
Dec-13-22 08:01AM
Nov-30-22 08:34AM
Nov-28-22 08:00AM
Nov-22-22 05:21AM
Nov-14-22 08:00AM
Sep-12-22 07:32AM
07:30AM Loading…
Sep-01-22 07:15AM
Aug-15-22 01:08PM
Jul-14-22 10:05AM
Jul-13-22 04:05PM
Jun-27-22 12:02PM
Jun-14-22 07:30AM
Jun-06-22 07:30AM
May-26-22 07:20AM
May-23-22 08:00AM
May-20-22 08:30AM
May-16-22 07:30AM
Apr-27-22 09:00AM
Apr-18-22 07:30AM
Apr-04-22 07:15AM
Mar-24-22 08:00AM
Mar-21-22 08:30AM
Mar-02-22 04:20AM
Feb-10-22 07:30AM
Jan-06-22 04:05PM
Jan-01-22 07:23AM
Dec-20-21 09:00AM
Nov-30-21 05:52AM
Nov-15-21 07:30AM
Nov-09-21 07:30AM
Nov-01-21 07:11AM
Oct-26-21 07:30AM
Oct-12-21 06:26AM
Oct-04-21 09:00AM
Sep-29-21 07:30AM
Sep-22-21 07:30AM
Aug-30-21 07:18AM
Aug-13-21 07:30AM
Jul-27-21 10:27PM
Jul-26-21 05:53AM
Jul-19-21 07:31AM
Jun-28-21 02:54AM
Jun-24-21 10:42AM
Jun-17-21 07:31AM
May-26-21 07:30AM
May-24-21 08:19AM
May-14-21 07:30AM
May-03-21 07:30AM
Apr-26-21 07:30AM
Apr-15-21 06:30PM
Apr-09-21 06:40AM
Mar-30-21 07:30AM
Mar-22-21 04:05PM
Mar-17-21 04:01PM
Mar-16-21 06:27AM
Mar-12-21 07:36AM
Mar-11-21 04:05PM
Feb-11-21 07:00AM
Dec-30-20 12:55AM
Dec-11-20 05:59PM
Nov-24-20 06:56AM
Nov-13-20 08:33AM
Oct-31-20 08:00AM
Oct-26-20 07:00AM
Oct-01-20 07:31AM
Sep-09-20 07:30AM
Aug-25-20 07:30AM
Aug-19-20 05:50AM
Aug-14-20 07:30AM
ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.